stockrowBristol Myers Squibb Company (BMY) vs Gilead Sciences, Inc. (GILD)
- Bristol Myers Squibb Company BMY 62.14 −1.57%
- Gilead Sciences, Inc. GILD 166.89 −0.41%
Bristol Myers Squibb Company and Gilead Sciences, Inc. are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $207.8B against $129.0B — 1.6× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Bristol Myers Squibb Company trades at 13.7×. Gilead Sciences, Inc. grew revenue faster over the last twelve months: 6.54% against 4.16%. Bristol Myers Squibb Company has the higher net margin (18.5% vs −12.5%) and the higher return on invested capital (13.2% vs −4.51%). Both pay a dividend; Bristol Myers Squibb Company yields more (4.06% vs 1.95%). Across the 22 metrics below, Bristol Myers Squibb Company leads on 15 and Gilead Sciences, Inc. on 7.
Valuation
Profitability
| Metric | BMY | GILD | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.24% | 79.93% | 73.01% |
| Operating margin | 22.65% | (7.63%) | 18.34% |
| Net margin | 18.47% | (12.47%) | 7.31% |
| Free cash flow margin | 18.56% | 44.47% | 18.56% |
| Return on equity | 44.01% | (22.45%) | 5.80% |
| Return on assets | 9.96% | (7.03%) | 2.28% |
| Return on invested capital | 13.19% | (4.51%) | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack